UBS AM’s Kyntra Bio KYNB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-4,203
| Closed | -$1.96M | – | 2622 |
|
|
2023
Q2 | $1.96M | Hold |
4,203
| – | – | ﹤0.01% | 1654 |
|
|
2023
Q1 | $1.96M | Buy |
4,203
+115
| +3% | +$60.8K | ﹤0.01% | 1654 |
|
|
2022
Q4 | $1.64M | Buy |
4,088
+826
| +25% | +$316K | ﹤0.01% | 1624 |
|
|
2022
Q3 | $1.06M | Sell |
3,262
-241
| -7% | -$77.6K | ﹤0.01% | 1933 |
|
|
2022
Q2 | $925K | Sell |
3,503
-109
| -3% | -$27.8K | ﹤0.01% | 2006 |
|
|
2022
Q1 | $1.09M | Buy |
3,612
+785
| +28% | +$274K | ﹤0.01% | 2086 |
|
|
2021
Q4 | $997K | Sell |
2,827
-537
| -16% | -$167K | ﹤0.01% | 2213 |
|
|
2021
Q3 | $860K | Buy |
3,364
+74
| +2% | +$26.2K | ﹤0.01% | 2250 |
|
|
2021
Q2 | $2.19M | Sell |
3,290
-502
| -13% | -$289K | ﹤0.01% | 1803 |
|
|
2021
Q1 | $3.29M | Buy |
3,792
+6
| +0.2% | +$6.39K | ﹤0.01% | 1533 |
|
|
2020
Q4 | $3.51M | Buy |
3,786
+253
| +7% | +$266K | ﹤0.01% | 1447 |
|
|
2020
Q3 | $3.63M | Buy |
3,533
+543
| +18% | +$584K | ﹤0.01% | 1286 |
|
|
2020
Q2 | $3.03M | Sell |
2,990
-93
| -3% | -$86.4K | ﹤0.01% | 1347 |
|
|
2020
Q1 | $2.68M | Sell |
3,083
-9,346
| -75% | -$9.29M | ﹤0.01% | 1296 |
|
|
2019
Q4 | $13.3M | Hold |
12,429
| – | – | 0.01% | 864 |
|
|
2019
Q3 | $11.5M | Buy |
12,429
+635
| +5% | +$697K | 0.01% | 915 |
|
|
2019
Q2 | $13.3M | Sell |
11,794
-2,417
| -17% | -$2.65M | 0.01% | 871 |
|
|
2019
Q1 | $19.3M | Sell |
14,211
-227
| -2% | -$308K | 0.01% | 749 |
|
|
2018
Q4 | $16.7M | Buy |
14,438
+5,216
| +57% | +$5.86M | 0.01% | 741 |
|
|
2018
Q3 | $14M | Sell |
9,222
-333
| -3% | -$513K | 0.01% | 849 |
|
|
2018
Q2 | $15M | Sell |
9,555
-543
| -5% | -$708K | 0.01% | 845 |
|
|
2018
Q1 | $11.7M | Sell |
10,098
-201
| -2% | -$265K | 0.01% | 898 |
|
|
2017
Q4 | $12.2M | Buy |
10,299
+1,604
| +18% | +$2.01M | 0.01% | 868 |
|
|
2017
Q3 | $11.7M | Buy |
8,695
+329
| +4% | +$347K | 0.01% | 865 |
|
|
2017
Q2 | $6.76M | Buy |
8,366
+7,898
| +1,688% | +$5.5M | 0.01% | 967 |
|
|
2017
Q1 | $288K | Buy |
+468
| New | +$285K | ﹤0.01% | 2026 |
|
|
2016
Q4 | – | Sell |
-9,214
| Closed | -$4.77M | – | 2545 |
|
|
2016
Q3 | $4.77M | Sell |
9,214
-279
| -3% | -$131K | 0.01% | 1033 |
|
|
2016
Q2 | $3.9M | Buy |
9,493
+3,152
| +50% | +$1.44M | ﹤0.01% | 1092 |
|
|
2016
Q1 | $3.37M | Sell |
6,341
-1,878
| -23% | -$936K | ﹤0.01% | 1148 |
|
|
2015
Q4 | $6.26M | Buy |
8,219
+7,355
| +851% | +$4.88M | 0.01% | 993 |
|
|
2015
Q3 | $474K | Sell |
864
-4,471
| -84% | -$2.71M | ﹤0.01% | 2047 |
|
|
2015
Q2 | $3.13M | Sell |
5,335
-173
| -3% | -$101K | ﹤0.01% | 1213 |
|
|
2015
Q1 | $4.32M | Sell |
5,508
-140
| -2% | -$109K | ﹤0.01% | 1087 |
|
|
2014
Q4 | $3.86M | Buy |
+5,648
| New | +$3.63M | ﹤0.01% | 1099 |
|
Other funds holding KYNB
AC
UBS AM's KYNB Position: Q3 2023 in Review
UBS AM sold out of Kyntra Bio (KYNB) in Q3 2023, closing a stake of 4,203 shares — an estimated $1.96M sold.
UBS AM first reported a position in KYNB in Q4 2014 and held it in 34 quarters. The position peaked at $19.3M in Q1 2019. 110 funds tracked by Wall St. Rank hold KYNB as of Q3 2023.
- UBS AM reported no remaining Kyntra Bio position as of Q3 2023 after selling out during the quarter.
- UBS AM sold 4,203 Kyntra Bio shares in Q3 2023, an estimated $1.96M.
- UBS AM first reported a position in Kyntra Bio in Q4 2014 and held it in 34 quarters.
- UBS AM's Kyntra Bio position peaked at $19.3M in Q1 2019.
- 110 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2023.
Based on UBS AM's 13F filing for Q3 2023, filed 13 Nov 2023.